"The blood-brain barrier represents a considerable hurdle for drug delivery to the brain. A new study in Science describes a platform that uses the transferrin receptor (TfR) expressed on brain endothelial cells to transport a therapeutic antibody targeting amyloid-beta (Aβ) into the mouse brain. This approach showed improved brain distribution and safety compared with unshuttled Aβ-targeting antibodies."
"A new study in Science describes a platform that uses the transferrin receptor (TfR) expressed on brain endothelial cells to transport a therapeutic antibody targeting amyloid-beta (Aβ) into the mouse brain. This approach showed improved brain distribution and safety compared with unshuttled Aβ-targeting antibodies."
The blood–brain barrier severely limits therapeutic access to the brain. A platform uses the transferrin receptor (TfR) on brain endothelial cells to shuttle a therapeutic antibody that targets amyloid-β (Aβ) into mouse brain. The TfR-mediated transport increases antibody penetration and distributes the therapeutic throughout brain tissue. Compared with unshuttled Aβ-targeting antibodies, the TfR-shuttled antibody shows improved brain distribution and an enhanced safety profile in mice. The approach leverages endogenous receptor-mediated transcytosis pathways to overcome vascular restriction and to reduce peripheral exposure. This method supports more effective delivery of large biologics to the CNS.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]